Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00

Key Points

• Chardan Capital raised its price target on SAB Biotherapeutics to $14.00 from $12.00 and maintained a "buy" rating, implying roughly a 206% upside from the prior close.
• The stock rallied about 11.6% to $4.58 on heavy volume (2.52M shares), pushing its market cap to roughly $218 million and trading well above recent moving averages.
• Analyst views are mixed: MarketBeat's consensus is a Moderate Buy with an average target of $10, while individual firm targets range from $7 to $15 and ratings include buys, holds and sells.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) had its target price boosted by analysts at Chardan Capital from $12.00 to $14.00 in a report released on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Chardan Capital's target price would suggest a potential upside of 206.01% from the stock's previous close.

Other analysts also recently issued reports about the company. Wall Street Zen raised SAB Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 22nd. HC Wainwright decreased their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday. Weiss Ratings restated a "sell (d)" rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. UBS Group began coverage on shares of SAB Biotherapeutics in a report on Wednesday, January 7th. They set a "buy" rating and a $7.00 price objective on the stock. Finally, Guggenheim assumed coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They issued a "buy" rating and a $15.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $10.00.

SAB Biotherapeutics Stock Up 11.6%

SABS traded up $0.48 during mid-day trading on Wednesday, reaching $4.58. 2,522,939 shares of the stock were exchanged, compared to its average volume of 455,720. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The stock has a market capitalization of $217.82 million, a PE ratio of -1.96 and a beta of 0.59. The company has a 50 day moving average price of $3.98 and a two-hundred day moving average price of $3.33.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.30). As a group, research analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at $22,954,000. RA Capital Management L.P. purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth $8,847,000. Commodore Capital LP bought a new stake in SAB Biotherapeutics during the third quarter valued at $8,847,000. Woodline Partners LP purchased a new position in SAB Biotherapeutics during the third quarter worth about $5,730,000. Finally, Spruce Street Capital LP bought a new position in SAB Biotherapeutics in the 4th quarter worth about $8,222,000. Institutional investors own 7.82% of the company's stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.